Immune checkpoint inhibitors (ICIs) exert the antitumor efficacy depending on immune response, which is affected by sex difference, where both biological and sociological factors are involved. The role of sex in ICI trials has been overlooked. How sex correlates with ICI efficacy is incompletely understood. Clinical trials evaluating ICI versus other therapies in male and female patients were included. The hazard ratio (HR) and 95% confidence interval (CI) of overall survival (OS) and progression-free survival (PFS) were used. Six thousand and ninety-six patients from 11 trials were included. More improvement of OS was observed in males (HR, 0.62; 95% CI, 0.53-0.71; p < 0.001) treated with ICI versus controls than females (HR, 0.74; 95% CI, 0.65-0.84; p < 0.001). ICIs improved PFS more in males (HR, 0.57; 95% CI, 0.43-0.71; p < 0.001) than females (HR, 0.71; 95% CI, 0.52-0.91; p < 0.001). The sex difference had more effect on the overall survival in melanoma patients versus NSCLC patients. Overall survival of patients treated with CTLA-4 inhibitor was more influenced by sex variable compared with PD-1 inhibitors. A significant sex-related efficacy difference was observed between female and male melanoma patients. Although male patients had longer OS and PFS than females when treated with ICIs versus controls, the difference was not significant. Sex difference should be more considered in future clinical trials, guidelines and clinical practice.
The invention of immune checkpoint inhibitor (ICI) is a scientific turning point for cancer treatment. 1, 2 Most recently, CTLA-4 and PD-1 inhibitors proved to prolong patients' survival based on the latest phase III trials. 3 CTLA-4 inhibitors can activate a broad spectrum of T cells at the initial stage of maturation, thus leading to a wide and non-specific immune response. In contrast, anti-PD-1 agents restimulate previously primed T cells which have lost effector and proliferative function. 4 Sex difference affects immune responses, 5 where both biological factors (hormonal and genetic factors) and sociological factors (gender difference) are involved. 5, 6 Sex chromosomes, genetic polymorphisms, oestradiol and progesterone have biological sex-dependent impacts on immune function. Likewise, gender difference-including health care access, social identity and food intake-tends to affect the immune system. 5, 6 From a preclinical perspective, sex difference is correlated with programmed death-ligand 1 (PD-L1)-mediated Treg function. 7 Based on this research, PD-L1 immune checkpoint inhibitor appears to be more efficacious in female patients, regardless of valid clinical evidence. To date, no preclinical observation manifested the association between sexrelated immune function and CTLA-4/PD-1 signaling. In the clinic, sex was associated with immune response to vaccination and mortality of malignant cancer. 5, 8 In the field of ICI, it was observed that ipilimumab-related hypophysitis differs in females and males. 9 Based on published trials, males seemed to benefit more from CTLA-4 or PD-1 inhibitors. Although several ICI clinical trials depicted this phenomenon, few clinicians attached importance to it. 10, 11 Chances are that the relatively small sample size prevented a sufficient statistical power. Large heterogeneity between sex-related effectiveness of PD-1 and CTLA-4 inhibitors was noted. Furthermore, in the clinical practice of ICI, clinicians and guidelines did not usually consider the impact of sex difference on the efficacy. The role of sex in ICI trials has been overlooked. Currently, how sex correlates with ICI effectiveness is incompletely understood. We postulated that the efficacy of ICI correlates with the sex variable. To address this hypothesis, we conducted a meta-analysis of 6,097 patients to compare the efficacy of CTLA-4 inhibitor and PD-1 inhibitors in males and females.
Methods

Study design and search strategy
This meta-analysis was based on data from published clinical trials that compared ICIs with other therapies in males and females. We searched for trials on PubMed/Medline, Embase, the Cochrane Central Register of Controlled Trials (CEN-TRAL), and Google Scholar in accordance with the PRISMA guideline; August 2017 was the cutoff date. Key words included CTLA-4, PD-1, immune checkpoint inhibitors, sex and clinical trial. We included only studies published in English. Trials were eligible for inclusion if they met five criteria. 
Data extraction
Three reviewers (Y.W., B.L. and K.J.) independently extracted data with a piloted extraction form, and checked all data carefully. We identified all studies by first author and the year of publication, and extracted the following information from the reports: year of publication, inclusion or exclusion criteria, sample size, drugs and doses in the experimental groups and control groups, HR of PFS or OS in males and females. The primary outcome measured in the meta-analysis was the OS, and the secondary outcome was the PFS. All the duplicated studies were excluded.
Risk of bias assessment
Three reviewers (Y.W., B.L., and K.J.) independently evaluated the result of risk of bias generated by the RobotReviewer tool. 12 All disagreements were resolved by the first author (YW). Details on the risk of bias in eight studies are illustrated in Supporting Information, Figure S2 . 
Statistical analysis
Results
Patient characteristics
The analysis was based on 11 trials 11,14-23 (Table 1) , in which 6,096 patients were included. The trial selection process was illustrated in Supporting Information, Figure S1 . Nine phase III trials, one phase II/III trial and one phase II trial were included. All the studies assessed the efficacy of CTLA-4 or PD-1 inhibitors (n 5 3,584) versus chemotherapies or other therapies (n 5 2,512). In total, data from 6,096 patients were included in the meta-analysis, of whom 2,541 had melanoma (5 trials) and 2,192 had NSCLC (4 trials). Besides, 821 patients had renal-cell carcinoma (1 trial) and 542 patients had urothelial carcinoma (1 trial). A total of 3095 male patients and 2191 female patients were included.
Primary outcome: overall survival
The comparison of HR for OS was based on 5,251 patients from nine trials. 11, [14] [15] [16] [17] 19, [21] [22] [23] A fixed model was used because there was a moderate heterogeneity (I 2 5 38.1%). We also conducted a subgroup analysis by the type of cancer (melanoma vs NSCLC) and the type of ICI (CTLA-4 inhibitor vs PD-1 inhibitors). Renal-cell carcinoma and urothelial carcinoma were not included in subgroup of cancer type because of the small sample size. ICI prolonged the OS significantly among the males (HR, 0.62; 95% CI, 0.53-0.71; p 5 0.000) and females (HR, 0.74; 95% CI, 0.65-0.84; p 5 0.000) in comparison with controls ( Figs. 1 and 2 ). Both the males and females had longer OS in all treatments than control groups, except nivolumab in female melanoma patients compared with ICC. 17 The metaanalysis showed that among all the comparisons, OS of male What's new? A patient's gender is rarely considered during cancer therapy. However, it is possible that the effectiveness of therapies involving the immune system may differ between males versus females, as many immune functions differ according to sex. In this meta-analysis, the authors analyzed the efficacy of immune-checkpoint inhibitors in melanoma patients. They found that there do indeed appear to be significant sex-related differences in the efficacy of these drugs. These results suggest that sex differences should be given greater weight in future clinical trials, guidelines and clinical practice.
patients was longer than female patients. Notably, the overall result of OS manifested that males appeared to benefit more from ICI treatment than females (Table 2) . According to the subtype analysis by cancer type, sex difference had more effect on OS of melanoma patients versus NSCLC patients (Table 2) . Also, in anti-CTLA-4-mAb group, the OS difference was more obvious between males and females compared with anti-PD-1-mAb group (Table 2) . Notably, among melanoma patients, a significant sex-related efficacy difference was observed between females and males (p 5 0.016).
Secondary outcome: progression-free survival A total of 2,150 patients from 4 trials were available for PFS analysis. 18, 20, 21, 23 A random model (I-V heterogeneity) was applied due to the high heterogeneity (I 2 5 63.8%). All the experimental groups were treated with anti-PD-1 drugs, while control groups were all chemotherapy treatments. Data related to CTLA-4 inhibitors were absent. Subgroup analysis by the type of cancer (melanoma and NSCLC) was performed.
A longer PFS was observed in both male patients (HR, 0.57; 95% CI, 0.43-0.71; p 5 0.000) and female patients (HR, 0.71; 95% CI, 0.52-0.91; p 5 0.000) (Figs. 3 and 4) . Male patients and female patients had a longer PFS in all treatments compared with chemotherapy, instead of pembrolizumab in female advanced-NSCLC patients versus docetaxel (HR, 1.02; 95% CI, 0.78-1.32; p 5 0.885). Among all the comparisons between ICI immunotherapy versus chemotherapy, males had longer PFS than females. Based on subgroup analysis by cancer type, sex difference had more effect on PFS in NSCLC patients than melanoma patients (Table 2) .
Publication bias and sensitivity analysis
Based on Begg's test and Egger's test for small-study effects, there was no publication bias. In Egger's test, the p values were 0.453 for OS and 0.161 for PFS. In Begg's test, the continuity-corrected p values were 0.496 for OS and 0.721 for PFS. These results indicated that there is no publication bias. We have also conducted the sensitivity analysis, and no significant result was observed (data not shown).
Discussion
The purpose of our study was to verify our hypothesis that the efficacy of PD-1 inhibitors and CTLA-4 inhibitor varies in males and females. Several preclinical and clinical trials of ICI depicted this phenomenon, 10,14-16,24,25 nevertheless, the lack of sufficient statistical power may cause controversy and inaccuracies. This meta-analysis indicated that males benefits more from CTLA-4 inhibitor (ipilimumab) and PD-1 inhibitors (nivolumab and pembrolizumab) than females ( Table 2) . This finding was consistent with several clinical trials which included a comparatively smaller sample size. 15, 16, 20 In males and females, we also compared the efficacy of PD-1 versus CTLA-4 inhibitors and melanoma subgroup versus NSCLC subgroup, finding that the sex-related efficacy difference was more obvious in CTLA-4 subgroup and melanoma subgroup. The observed results may not be entirely applicable to patients treated in the clinical practice. In female patients, there were some specific ICIs associating with no survival advantage compared with chemotherapy. Melanoma patients in treatment with nivolumab did not have a longer OS compared with ICC. Also, no longer PFS of female advanced-NSCLC patients treated with pembrolizumab was observed as opposed with docetaxel. This should be appreciated in the clinical practice.
In preclinical settings, it was recently reported that sex difference associates with mammalian traits based on data from 14,250 wildtype and 40,192 mutant mice. 26 Likewise, from a clinical perspective, another research discussed the sex-based subgroup differences from empirical evidence in Cochrane meta-analyses. 27 In accordance with these findings, our study also indicated the impact of sex on ICIs efficacy.
The preclinical rationale for our result still remains unknown. A preclinical study emphasized that PD-L1 molecular is sex-related, leading to different tumor immunity and immunotherapy responses in males and females. 7 They also hypothesized that PD-L1 inhibitors would consequently become more efficacious in females. Similarly, our research was focused on correlation between sex and efficacy of CTLA-4 and PD-1 inhibitors; however, analysis of PD-L1 inhibitors was not performed due to the lack of data. More broadly, numbers of preclinical studies had shed light on the association between sex difference and lymphocytes. 5 Interestingly, Liva et al. found that testosterone acts directly on CD4
1 T lymphocytes to increase IL-10 production in mice, 28 which could be a possible preclinical rationale of our result. Although this finding merely represented one aspect of correlation between sex and ICI efficacy, their results manifested that efficacy of immunotherapy may not be equally effective in male and female patients, and ICI may appear more beneficial in male patients. The sample sizes of all the trials of CTLA-4 inhibitor (ipilimumab) and PD-1 inhibitors (nivolumab and pembrolizumab), which conducted subgroup analyses by sex type, were not large enough to generate sufficient statistical power. Among all the included trials, the KEYNOTE-010 trial 21 enrolled the largest number patients and the largest number of female patients, which reported the outcome of 1033 patients including 399 female patients (39%). In this KEYNOTE-010 trial 21 which evaluated efficacy of pembrolizumab versus docetaxel in advanced NSCLC, a better OS outcome of male patients (HR, 0.65; 95% CI, 0.52-0.81) was observed compared with females (HR, 0.69; 95% CI, 0.51-0.94). Also, PFS of males (HR, 0.78; 95% CI, 0.64-0.94) was longer than females (HR, 1.02; 95% CI, 0.78-1.32). These results were in accordance with our conclusion.
Paradoxically, some preclinical studies indicated that females rather than males, contrary to our result, should benefit more from immunotherapy. In particular, androgen deprivation upgrades levels of T cells in peripheral lymphoid tissues in mice 29 and the function of PD-1 inhibitor relies on immune priming in peripheral lymphoid tissues. 30 Hence, their results indicated a possibility that females will benefit more from PD-1 inhibitor. On the contrary, two clinical trials 14, 15 and our result showed the opposite. A dialogue between preclinical researches and clinical findings is required for the better understanding and application of ICI immunotherapy.
Our study has several potential limitations because studies on multiple types of cancer with different etiologies and disease courses were included. We had no access to more data especially the PFS of patients, precluding a more detailed appraisal of outcomes, and, the safety profile of males and females were totally unavailable. Another concern was that PFS analysis was based on 2,150 patients from 4 trials despite the fact that we sought the most relevant databases to collect all published and presented trials. In the future, meta-analysis on toxicity of ICIs between males and females may get conducted, although valid data are currently absent. The preclinical mechanism is worth further investigations. A research conducted by wallach et al. 27 questioned the credibility of all sex-related meta-analyses. The authors specified that sex-based subgroups should be tested only when there is a priori credible biological rationale. In accordance with their research, evidences have shown that androgen deprivation upgrades levels of T cells in peripheral lymphoid tissues in mice, 29 and the function of PD-1 inhibitor relies on immune priming in peripheral lymphoid tissues. Hence, prior biological evidence indicates the possible sex-efficacy correlation of PD-1 inhibitors. Also, the conclusions of that BMJ paper are largely based on the fact that many sex-treatment interactions in the forest plots from the CDSR were calculated through data from only one RCT. However, results of significant sex-efficacy difference in melanoma patients are based on 5 data sources. This may increase the credibility of our analysis. Sex is a biological variable that should be considered in subsequent ICI clinical trials, although only a few of them conducted a subgroup analysis by sex. Also, guideline developers should take sex into consideration when issuing formulations and dosage recommendations in the field of ICI. Female patients should be offered ICI immunotherapies, and female patients should be encouraged to participate in ongoing and future trials of ICI drugs. In the clinical practice of ICI, sex difference should be taken into more consideration.
In summary, a significant sex-related efficacy difference was observed between female and male melanoma patients. Overall survival of patients treated with CTLA-4 inhibitor was more influenced by sex variable compared with PD-1 inhibitors. Female melanoma patients in treatment with nivolumab did not have longer overall survival compared with ICC. No longer PFS of female advanced-NSCLC patients treated with pembrolizumab was observed versus docetaxel. Sex difference should be taken into more consideration in future clinical trials, guidelines and clinical practice. Correlation between sex and ICI efficacy should not be ignored by the scientific community any more.
